刘新泳，男，汉族，1963年3月出生，山东人。研究生学历，博士学位，教授，访问学者，山东大学校聘二级岗教授，博士生导师，享受国务院政府特殊津贴。现任致公党山东省委会副主委、致公党山东大学基层委员会主委，济南市历下区人大代表，山东大学药学院院长。
1980年考入山东医学院药学系，1984年毕业，获得学士学位，同年留校任教（助教）。1988年考入山东医科大学药物化学专业研究生，1991年毕业，获理学硕士学位，同年留校任教。1992年晋升讲师，1994年破格晋升为副教授、硕士导师。1997年3月—1999年3月，02年4-9月两度赴西班牙国家科学院药物研究所，作为访问教授从事国际合作课题研究，2001年晋升教授。2001年考入山东大学药物化学专业博士生，2004年获博士学位。2004年山东大学校聘关键岗教授，2009年山东大学校聘二级岗教授。2017年5月致公党山东省委会副主委。
2017年5月16日，致公党山东省第六次代表大会在济南闭幕，当选为副主任委员。
研究生：现代有机合成化学；现代药物制备与分离技术。本科生：生物有机化学；药学英语；无机化学等。① 基于靶点的抗病毒药物的合理设计、合成与活性研究。本研究方向主要基于病毒（HIV、HBV和FluV）生命周期的分子生物学过程，针对病毒复制过程的关键酶或蛋白等靶点结构，通过计算机辅助，进行合理药物的设计、合成及抗病毒活性的研究。主要开展基于HIV-1逆转录酶的非核苷类抑制剂、核苷类及其大分子缀合物的前药研究；开展基于HIV-1侵入过程病毒gp120吸附抑制剂和辅助受体CCR5拮抗剂研究；开展基于HIV-1转录过程Tat-TAR相互作用、Rev-REE相互作用抑制剂的研究。同时，开展基于HBV侵入和包装过程的非核苷类抗乙肝病毒抑制剂研究；开展基于流感病毒神经氨酸酶、DNA聚合酶为靶点的抑制剂研究。　　② 基于活性天然产物的结构修饰与心脑血管药理活性的研究。本研究方向主要开展活性天然产物的全合成、结构修饰和抗缺血、抗血栓、抗血脂、抗氧化损伤等心脑血管活性研究。主要开展中药川芎活性成分川芎嗪、川芎咔啉碱衍生物的结构修饰研究。在从事抗病毒药物研究方面，曾主持科技部中国-西班牙政府间国际合作课题“含硫杂环化合物的合成及其生物活性研究”(1997.1-1999.12)和“新型蒽醌酮类化合物的合成及其抗病毒、抗肿瘤活性研究”(2002.1-2004.12)；主持科技部国际合作重点项目“新型非核苷类HIV逆转录酶抑制剂的研究”（303DF000033，2003.10-2006.12，50万）；主持国家自然基金“噻吩并噻二嗪新型非核苷类HIV逆转录酶抑制剂的研究”（30371686, 2004.1-2006.12）、“取代噻二嗪类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究”（30873133；2009.1-2011.12）、 “吡咯并噻三嗪类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究”（30772629，2008.01-2010.12）、“靶向于HIV-1多靶点蛋白gp120的非等同双靶点抑制剂研究”（国家自然基金-海外和港澳学者合作基金，30928031, 2010.01-2012.12 国内课题主持人）；另外，主持山东省自然基金等课题；　　在从事心脑血管药物研究方面，曾主持国家重大新药创制科技专项—候选药物 “川芎嗪阿魏酸酯抗心脑血管疾病候选药物研究”（ 2009ZX09103-117，科技部，2009.1-2012.1）、山东省科技发展计划项目（2006GG2202063 2007.1-2009.12）、山东省自然基金、山东省1020计划、济南市青年科技明星计划项目等课题研究。1）新型六元芳杂环类抗耐药性HIV-1 NNRTI的设计、合成与活性研究. 国家自然基金，项目编号: 81273354, 2013.01-2016.12 课题主持人2）新型HEPT类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究，国家自然基金重大国际合作项目，项目编号: 30910103908; 2010.01-2013.12 课题主持人　　3). 三苯双咪国际合作项目（新华制药联合项目），国家重大新药创制：山东省创新药物孵化基地建设，（2010ZX09401-302-3-1），2010.5-2013.5　　4). 阿司匹林原料药技术改造（新华制药联合项目），国家重大新药创制“125”第一批项目（2011ZX09203-001-01）：2011.5-2014.55) 新型抗耐药性HEPT类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究. 教育部博士点基金—优先发展领域课题。项目编号: 20110131130005。 2011.1-2013.12, 主持人　　6） 取代噻二嗪类HIV-1非核苷类逆转录酶抑制剂的设计合成及活性研究。 山东省自然基金，项目编号: ZR2009CM016 2009.12-2012.12 课题主持人现任药学院副院长，药物化学研究所所长，教研室主任；山东省新药设计与创新药物研究重点实验室主任；山东省保健科技协会常务理事；国家SFDA保健食品审评专家、国家科学技术奖励评审专家、科技部国际合作重点项目评审专家；山东省药学会理事、副秘书长；国际杂志“E-Journal of Chemistry (IF0.58)”学术编辑（Academic Editor）；国际著名期刊 “Current Medicinal Chemistry”(IF4.961)、“Drug Discoveries & Therapeutics”、“World Journal of Virology”、“World Journal of Pharmacology”、“World Journal of Clinical Infectious Diseases” “Virology Discovery”、“Interactive Medicinal Chemistry” 编委；《中国药物化学杂志》、《中国医药工业杂志》、《山东大学学报（医学版）》编委；山东省药学会药物化学专业委员会委员。近几年在 中国化学、有机化学、药学学报、中国药学杂志、中国药物化学杂志、中国医药工业杂志等发表文章200余篇；其中被SCI收录余篇（论文见附录）；主编《抗艾滋病药物研究》专著（人民卫生出版社，北京，2006年12月）、主编《有机化合物制备与分离技术》专著（人民卫生出版社，北京，2011年2月）、主编《无机化学》、 副主编《无机化学教程》教材；参编《分子核医学》、《现代生物医学示踪技术》(王世真院士主编) 等专著6部。曾荣获山东省科技进步一等奖1项（第二，2012）；山东省教育厅科技进步三等奖2项，山东省高等学校优秀科研成果奖一等奖、二等奖各1项（第一，2010、2005）；申报国家发明专利30余项，其中已获得发明专利授权17项；曾获2001山东省青年科技奖、2004山东省优秀中青年重点科技人才、2004年济南市青年科技明星奖、2002年山东大学优秀青年知识分子、2007年山东大学十大优秀教师、2009和2012年度山东大学优秀研究生指导教师，2009山东大学十大新闻人物提名奖、2010 山东省医学领军人才、2011获享受国务院政府特殊津贴等荣誉称号。　　曾经与企业合作，成功开发了头孢地嗪抗生素、抗心律失常药物尼非卡兰、抗菌药物奥硝唑分散片、抗病毒药物泰诺福韦酯原料及片剂、质子泵抑制剂埃索美拉唑镁、钠等仿制药物，为企业创造了较大的经济和社会效益。　　1．刘新泳, 徐文方 等，川芎醇酯类衍生物及其制备方法和含有川芎醇酯类衍生物的药物组合物与应用。中华人民共和国国家知识产权局，中国发明专利， ZL02135989.X , 2005-1-12　　2．刘新泳，徐文方, 程先超 等 川芎嗪烃基哌嗪类衍生物、制备方法和药物组合物与应用。 中华人民共和国国家知识产权局， 中国发明专利，专利号：ZL200510045307.4，（2007-7-18）　　3．刘新泳，徐文方, 闫任章 等. 2，4-二取代杂环并[4,5-e][1,2,4]噻二嗪衍生物制备方法. 中华人民共和国国家知识产权局。专利号：ZL2006 1 0043834.6 2008-6-11　　4. 刘新泳，徐文方, 闫任章 等. N4-取代吡唑[4,5-e]]1,2,4]噻二嗪类衍生物、制备方法及其药物组合物与应用。 中华人民共和国国家知识产权局。专利号：ZL200510044297.2 2009-5-6　　5. 刘新泳，徐文方, 林永强 等. N1,N3-二取代噻吩并[3,2-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物与应用。中华人民共和国国家知识产权局。专利号：ZL 200610043833.1， 2009年6月17日　　6. 刘新泳，李锦 等. N1，N3-二取代吡唑并[4,5-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物及其制备方法与应用。专利号：ZL200710015052.6 中华人民共和国国家知识产权局，2009年7月29　　7. 刘新泳, 常昱 等. 聚乙二醇修饰齐夫多定缀合物及其制备方法与应用，中华人民共和国国家知识产权局，专利号： ZL200710015587.3, 授权日：2010-1-21 。　　8.刘新泳，邓利娟 等, 川芎嗪茋类衍生物、制备方法和药物组合物与应用。中华人民共和国国家知识产权局，专利号： ZL200710014906.9, 授权日：2010-2-03　　9. 刘新泳，于芳 等, 川芎嗪胍类衍生物的制备方法及其应用。中华人民共和国国家知识产权局。专利号： ZL200810157518.0, 授权日：2010-06　　10. 刘新泳，于芳等. 川芎嗪酰胺类衍生物、制备方法和药物组合物与应用。专利号：ZL200810157251.5, 授权日：2011-3-16　　11. 刘新泳, 展鹏等. 1，2，3-噻二唑巯乙酰胺类衍生物及其制备方法。专利号：ZL200910016414.2，授权日：2011-2-16　　12. 刘新泳, 于明艳等. 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3H-嘧啶-4-酮类衍生物及其制备方法与应用 ZL200910017725.0，授权日：2011.4.27　　13. 刘新泳, 展鹏等. -取代苯基-2-(1-芳基-1H-咪唑-2-巯基)乙酰胺类衍生物及其制备方法与应用. 专利号：ZL200810157250.0 授权日: 2011-4-27　　14．刘新泳, 展鹏, 方增军. 1，2，3-硒二唑巯乙酰胺类衍生物及其制备方法与应用。发明专利专利号：ZL200910016413.8，授权日: 2011-6-15　　15. 刘新泳, 展鹏, 方增军，李震宇. 取代噻唑巯乙酰胺类衍生物及其制备方法与应用。发明专利，专利号：ZL201010223400.0，授权日: 2012-7-25　　16. 刘新泳, 展鹏, 方增军。2-(2-取代芳基-2H-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用，发明专利，专利号：ZL201010223401.5，授权日: 2012-7-25　　17. 刘新泳，李震宇，展鹏。5-取代-2-（4-取代苯基）苯并恶唑类衍生物及其制备方法与应用。发明专利，专利号：ZL201110021056.1, 授权日:2012-10- 3　　1. Wenjun Li, Peng Zhan, Erik De Clercq, Hongxiang Lou*, Xingyong Liu*. Current Drug research on PEGytion with small molecular agents. , 2013; 38: 421-444. 　　2. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu*. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. , 2013; 33(S1): E1-E72 (IF=10.7)　　3. Yu’ning Song, Peng Zhan,* Dongwei Kang, Xiao Li, Ye Tian, Zhenyu Li, Xuwang Chen, Wenmin Chen, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of novel pyridaziylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. . 2013; 4(5): 810-816 　　4. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Erik De Clercq, Xinyong Liu*. Synthesis and anti-HIV evaluation of novel 1,2,4-triazole derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. ;  27-34　　5. Yu'ning Song, Peng Zhan, Qingzhu Zhang and Xinyong Liu*. Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry.  2013; 19(8): 1528-1548　　6. Peng Zhan, Xinyong Liu*. Multivalent agents: a novel concept for anti-HIV drug discovery. , 2013, 20(6): pp. 815-832　　7. Dongyue Li, Peng Zhan, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. . 2013; 21(7): 2128-34.　　8. Xuwang Chen, Shufang Ding, Peng Zhan and Xinyong Liu*. Recent Advances of Diaryl Ether Family as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. 2013; 19(15): 2829-2838　　9. Hongfei Chen, Guoning Li, Peng Zhan, Xiuli Guo, Qian Ding, Shouxun Wang and Xinyong Liu*. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. 2013, 4, 827-832　　10. SUN Sang-Dun, MI Si-Qi, YOU Jing, YU Ji-Liang, HU Song-Qing, LIU Xin-Yong. HQSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors[J]. , 2013, (6), 1192-1200　　11. Zhenyu Li, Fang Yu, Lei Cui, Chen Wenmin, Shouxun Wang, Peng Zhan, Xinyong Liu. Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents.  accepted　　12. Hongfei Chen; Guoning Li; Qian Ding; Lei Cui; Peng Zhan; Shouxun Wang; Xinyong Liu* Ligustrazine derivatives. Part 8: Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents., submitted　　13. Peng Zhan, Xiao Li, Diwakar Rai, Erik De Clercq and Xinyong Liu*. Rationally designed multivalent anti-HIV agents. 　　14. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Yuemao Shen and Xinyong Liu*. Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2013, 9, 000-000　　15. Tian Ye, Xinyong Liu*. Design, synthesis and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs (CBDD-RA-02-13-1571) . 　　16. Xuwang Chen, Yuanyuan Li, Shufang Ding, Jan Balzarini, Christophe Pannecouque, Erik De Clercq and Xinyong Liu. Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Acceptance of Your Manuscript cmdc.201300130 for ChemMedChem　　　　　　1. Dongyue Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of six representative candidates. , 2012, 55 (8), pp 3595–361. (IF= 5.2) (DOI: 10.1021/jm200990c)　　2. Xuwang Chen, Peng Zhan, Xin Liu, Ziheng Cheng, Caicai Meng, Siyuan Shao, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*, Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. , 2012: 20 : 3856–3864　　3. Wenjiun Li, Jingde Wu, Peng Zhan, Yu Chang, Christophe Pannecouque, Erik De Clercq & Xinyong Liu*. Synthesis, drug release and anti-HIV Activity of a series of PEGylated zidovudine conjugates. International Journal of Biological Macromolecules. 2012;50(4): 974-980　　4. Xuwang Chen, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2012; 51: 60-66　　5. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Structure-based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent HIV-1 NNRTIs. . 2012; 22: 7155–7162　　6. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of Novel 2-(3-(2-Chlorophenyl) pyrazin-2-ylthio)-N-arylacetamides As Potent HIV-1 Inhibitors Using a Structure-Based Bioisosterism Approach.  2012, Volume 20, Issue 23, Pages 6795–6802　　7. Xiao Li, Peng Zhan*, Hong Liu, Dongyue Li, Liu Wang , Xuwang Chen, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Arylazolyl(azinyl) thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.2012; 20: 5527-5536　　8. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu* Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and Biological Investigation of Thiazolylthioacetamides Derivatives as A Novel Class of Potential Antiviral Agents. , 2012;Vol 35, No 6, 975-986,　　9. Lijuan Deng, Xiuli Guo, Li Zhai, Yuning Song, Hongfei Chen, Peng Zhan, Jingde Wu, Xinyong Liu*. Ligustrazine derivatives. Part 4: Design, synthesis and biological evaluation of novel Ligustrazine-based stilbene derivatives as potential cerebrocardiac vascular agents.  2012 May ; 79 ( 5 ): 731-739 　　(DOI: 10.1111/j.1747-0285.2012.01332.x)　　10. Wenwen Chen, Peng Zhan, Erik De Clercq and Xinyong Liu*. Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors., 2012; 18(1): 4165-4186　　11. Zhenyu Li, Peng Zhan, Lieve Naesens, Evelien Vanderlinden, Ailin Liu, Guanhua Du, Erik De Clercq and Xinyong Liu*. Synthesis and preliminary biological evaluation of 5-substituted-2-(4- substituted phenyl) benzoxazoles as a novel class of influenza virus A inhibitors.  2012; 79 ( 6 ): 1018-24　　12. Ye Tian, Peng Zhan, Diwakar Rai, Jiyan Zhang, Erik De Clercq and Xinyong Liu*. Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 NNRTIs. , 2012; 19(13): 2026-2037.　　13. Wenmin Chen, Peng Zhan, Jingde Wu, Zhenyu Li and Xinyong Liu*. The Development of HEPT-type HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Its Implications for DABO Family. Current Pharmaceutical Design, 2012, 18, 4165-4186　　14. Xiaofei Jiang, Peng Zhan, Xinyong Liu* & Erik De Clercq. Synthesis and Anti-HIV Activity Evaluation of 2-(5-(Naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-N-acetamides Derivatives.  . 2012; 31 (5): 751-755　　15. Zhenyu Li, Fang Yu, Lei Cui, Peng Zhan, Shouxun Wang* and Xinyong Liu*. Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazine acylguanidine derivatives as potential cerebrocardiac vascular agents. . 2012 Jun 25. 2012;8(5):928-33.　　16. Xiao Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. The HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors (Part V): Capravirine and Its Analogues. , 2012; 19 ( 36): Pp.6138-6149　　17. Peng Zhan, Dongyue Li, Junyi Li, Xuwang Chen and Xinyong Liu*. Benzimidazole (Benzimidazolone) Heterocycle as A Privileged Scaffold in Antiviral Agents. , 2012, 9, 397-410　　18. Zhai L, Zhang P, Sun RY, Liu XY, Liu WG, Guo XL.Cytoprotective effects of CSTMP, a novel stilbene derivative, against HO-induced oxidative stress in human endothelial cells. . 2012, Nov;63(6):1469-80.　　　　　　1. Zhang Jing, Zhan Peng, Wu Jingde, Li Zhenyu, Jiang Yan, Ge Weiying, Pannecouque C, De Clercq E, Liu Xinyong*. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6- ((3,4-dihydroquinolin-1(2H)-yl)methyl) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.  2011; 19: 4366–4376　　2. Mingyan Yu, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonyl -methylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. 2011; 6(5): 826–833　　3. Mingyan Yu, Xinyong Liu*, Ailin Liu, Guanhua Du, Lieve Naesens, Evelien Vanderlinden, Erik De Clercq. Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents, 2011, 78(4): 596–602　　4. Peng Zhan, Xuwang Chen, Dongyue Li, Wenwen Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu. Arylazolylthioacetanilide part 8. Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamides As Potent HIV-1 Inhibitors. . 2011; 46 : 5039-5045　　5. Zhan Peng, Li Dongyue, Chen Xuwang, Liu Xinyong*, De Clercq Erik. Functional Roles of Azoles Motif in Anti-HIV Agents. , 2011; 18(1): 29-46　　6. Hongfei Chen, Peng Zhan, Xinyong Liu*. Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. . 2011;46: 5609-5615　　7. Zhan Peng, Liu Xinyong*. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).  (2011) ; 21(5):1-80　　8. Jiang Yan, Liu Xinyong*, De Clercq Erik. New Therapeutic Approaches Targeted at the Late Stages of the HIV-1 Replication Cycle. 2011; 18(1): 16-28　　9. Mingyan Yu, Erkang Fan, Jingde Wu and Xinyong Liu*. Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. 2011, 18(16): 2376-2385　　10. Zhang Jing, Ge Weiying, Zhan Peng, De Clercq E, Liu Xinyong*. Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication. 2011; 18(17): 2649-2654.　　11. Xuwang Chen, Peng Zhan, Dongyue Li, Erik De Clercq and Xinyong Liu*. Recent Advances in DAPYs and Related Analogues as HIV-1 NNRTIs., 2011, 18, 359-376　　12. Zhenyu. Li, Peng. Zhan and Xinyong Liu. 1,3,4-Oxadiazole: A in Antiviral Agents.  2011 11: 1130-1142　　13. Peng Zhan, Xuwang Chen, Xinyong Liu*, Christophe Pannecouque, Lieve Naesens, Erik De Clercq, Ailin Liu, Guanhua Du. Thiazolylthioacetamides as a Novel Class of Potential Antiviral Agents. , , , 　　14. Wenjun Li, Peng Zhan, Jingde Wu, Yu Chang, Christophe Pannecouque, Erik De Clercq, Xinyong Liu.* Synthesis, Influence of Polymer Molecular Weight on Drug Release and Anti-HIV Activity of PEGylated AZT Conjugates. , , , 　　15. Peng Zhan, Renzhang Yan, Xinyong Liu,*, Christophe Pannecouque, Myriam Witvrouw , Erik De Clercq, Maria Teresa Molina, Salvador Vega. Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl- 1,1,3-trioxo-,-pyrazolo[4,5-] [1,2,4]thiadiazine derivatives. 　　16. Hu Song-Qing, Mi Si-Qi, Jia Xiao-Lin, Fan Cheng-Cheng, Chen Sheng-Hui, Zhang Jun, Liu Xin-Yong*. 3D-QSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors.  2011, Vol. 32 Issue (10) :2402-2409　　17. Yu-Ning Song, Xiu-Li Guo, Bei-Bei Zheng, Xin-Yong Liu, Xue Dong, Lu-Gang Yu, Yan-Na Cheng. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. 2011; vol. 25, no. 4, pp. 937-943,　　　　　　1. Wenjun Li, Yu Chang, Peng Zhan, Na Zhang, Xinyong Liu,*Christophe Pannecouque, and Erik De Clercq. Synthesis, In Vitro and In Vivo Release Kinetics, and Anti-HIV Activity of A Sustained-Release Prodrug (mPEG-AZT) of 3’-Azido-3’-deoxythymidine (AZT, Zidovudine).  2010; 5: 1893-1898.　　2. Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole Thioacetanilides. Part 2. Synthesis and Biological Evaluation of a New Series of 2-(4-(3,4-dichlorophenyl)-1,2,3-Thiadiazol-5-ylthio)Acetamides as Anti-HIV-1 inhibitors. . 2010; 7: 1717-1726　　3.Yang Ou, Xue Dong, Xin-Yong Liu, Xian-Chao Cheng, Yan-Na Cheng, Lu-Gang Yu,nd Xiu-Li Guo*. Mechanism of Tetramethylpyrazine Analogue CXC195 Inhibition of Hydrogen Peroxide-Induced Apoptosis in Human Endothelial Cells. 2010; (3): 432-438　　4. Ou Y, Guo XL, Zhai L, Liu XY, Cheng YN. TMPDP, a tetramethylpyrazine derivative, protects vascular endothelial cells from oxidation damage by hydrogen peroxide.. 2010 Oct; 65(10):755-9.　　5. Peng Zhan, Hongbing Liu, Xinyong Liu*, Yan Wang, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq. Synthesis and anti-HIV activity evaluation of novel N-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides.  2010; 19:652–663　　6. Hongfei Chen, Xinyong Liu*, Peng Zhan and Erik De Clercq. TSG101: a Novel Anti-HIV-1 Drug Target. . 2010; 17(8): 750-758　　7. Peng Zhan, Xinyong Liu*, Erik De Clercq. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm., 2010; 17(6): 495-503 　　8. Peng Zhan, Xuemei Jiang, Xinyong Liu*. Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-nucleoside HBV Inhibitors. 2010 Feb;10(2):161-70.　　9. Peng Zhan, Zhenyu Li, Xinyong Liu*. Cosalane and Related Analogues: A Unique Class of Anti-HIV Agents. , 2010, 10, 966-976　　10.Zhan Peng, Li Wenjun, Chen Hongfei and Liu Xinyong*.Targeting Protein-Protein Interactions: A Promising Avenue of Anti-HIV Drug Discovery. , 2010; 17(6): 495-503 　　　　　　1. Peng Zhan, Xinyong Liu*, Zhenyu Li, Zengjun Fang, Zhong Li, Defeng Wang, Christophe Pannecouque, Erik De Clercq. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. , 2009; 17(16): 5920-5927. (15 August 2009).　　2. Mingyan Yu, Xinyong Liu*, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonyl methylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3)-ones as potent HIV-1 NNRTIs. , 2009;17: 7749–7754　　3. Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation . 2009; 17(16): 5733-6146　　4. Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. . 2009; 17(16): 5775-5781.　　5. Xinyong Liu*, Peng Zhan, Christophe Pannecouque, Erik De Clercq. Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides as Potent NNRTIS. , , , 　　6. Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5- ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. 2009; 44 : 4648–4653　　7.Xian-Chao Cheng, Xin-Yong Liu*, Wen-Fang Xu, Xiu-Li Guo Ning Zhang, Yuning Song Ligustrazine derivatives part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.  2009; 17: 3018–3024　　8. Yuan Cao, Xinyong Liu* and Erik De Clercq. Cessation of HIV-1 Transcription by Inhibiting Regulatory Protein Rev-Mediated RNA Transport., 2009, , 101-108　　9. Yu Mingyan, Liu Xinyong* and Erik De Clercq. NF-κB: The Inducible Factors of HIV-1 Transcription and their Inhibitors. 2009 9(1): 60-69　　10.  Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors. 　　11. Yan Wang, Xin-yong Liu* and Erik De Clercq. Role of the HIV-1 Positive Elongation Factor P-TEFb and Inhibitors Thereof. 2009379-385　　Peng Zhan and Xinyong Liu*. Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm. 2009;: 1893-1917　　13. Peng Zhan, Zhenyu Li, Xinyong Liu* Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs. 2009: 1014-1023　　14. Peng Zhan, Xinyong Liu* and Zhanyu Li. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update.  2009; 16(22): 2876-2889. (August 2009)　　15. Peng Zhan, Xinyong Liu*, Christophe Pannecouque, Erik De Clercq. Design Strategies of Novel NNRTIs to Overcome Drug Resistance.  2009; 16(29): 3903-3917.　　　　　　1. Peng Zhan, Xinyong Liu*, Yuan Cao, Yan Wang, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.  2008; Oct 15;18(20):5368-71.　　2. Peng Zhan, Xinyong Liu* and Erik De Clercq. Recent Advances in Antiviral Activity of Benzo/Heterothiadiazine Dioxide Derivatives. 2008; 15(15): 1529-1540.　　3. Yongqiang Lin, Xinyong Liu,* Renzhang Yan, Jin Li, Christophe Pannecouque, Myriam Witvrouw and Erik De ClercqSynthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-][1,2,6]thiadiazin-4(3)-one 2,2-dioxides (TTDDs). 2008; 16 (1): 157–163　　4. Xinyong Liu,* Ren-zhang Yan, Yan Wang, Peng Zhan, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq, Maria Teresa Molina and Salvador Vega. Synthesis and Anti-HIV Activity Evaluation of Novel 2,4-Disubstituted 7-Methyl-1,1,3-trioxo-24-Pyrazolo[4,5-] [1,2,4]thiadiazines. 2008; 341(4): 216-222　　5. Fang Yu, Xinyong Liu,* Peng Zhan and Erik De Clercq. Recent Advances in the Research of HIV-1 RNase H Inhibitors. 2008 Nov; 8(12):1243-51　　6. Xinyong Liu , Peng Zhan, Renzhang Yan, Yongqiang Lin, Jin Li,Christophe Pannecouque and Erik De Clercq. Design, Synthesis and Antiviral Evaluation of Novel Heterocyclic Compounds as HIV-1 NNRTIs. 　　　　　　1. Xian-Chao Cheng, Xin-Yong Liu,* Wen-Fang Xu, Xiu-Li Guo and Yang Ou. Design, synthesis and biological activities of novel Ligustrazine derivatives.  2007; 15(10): 3315–3320　　2. Jingde Wu, Xinyong Liu *, Xianchao Cheng , Yuan Cao, Defeng Wang , Zhong Li, Wenfang Xu , Christophe Pannecouque , Myriam Witvrouw and Erik De Clercq. Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. 20072003-2016.　　3. Xin Yong LIU*, Ren Zhang YAN, Nian Gen CHEN, Wen Fang XU . Regioselective Synthesis and Anti-HIV Activity of the Novel 2- and 4-Substituted Pyrazolo[4,5-][1,2,4]thiadiazines.  2007;18: 137-140　　4. Xin-Yong Liu*, Xian-Jun Qu, Wei Tang. China-Japan enhance joint research cooperation for drug discoveries and development: News from CJMWDDT 2007 in Jinan, China. 　　　　　　1. Xinyong Liu* Niangen Chen, Renzhang Yan, Wenfang Xu, Maria Teresa Molina, and Salvador Vega Regioselective Synthesis of the Novel -Substituted Pyrazolo[4,5-][1,2,4] thiadiazines as Potent HIV-1 NNRTIs. , 2006; 68(6): pp.1225-1232　　2. Xinyong Liu*, Renzhang Yan, Niangen Chen, Wenfang Xu, Maria Teresa Molina and Salvador Vega. Regioselective Synthesis of Novel - and -Substituted 7-Methylpyrazolo [4,5-e] [1,2,4]thiadiazines,  2006, : 827-836　　3. Xianchao Cheng, Xinyong Liu*, Wenfang Xu. Synthesis of Novel Ligustrazine Derivatives as Potential Platelet Aggregation Inhibitors.  2006; Vol. 17, No. 10, pp 1317-1320　　4. Xian-chao Cheng, Xin-yong Liu* and Wen-fang Xu .The preparation of novel ligustrazine derivatives as potential cerebrocardiac vascular agents. 2006; September, 577–579　　5. Ren-Zhang Yan, Xin-Yong Liu*, Wen-Fang Xu, Christophe Pannecouque1, Myriam Witvrouw, and Erik De Clercq. Synthesis and Anti-HIV Evaluation of the Novel 2-(m-Chlorobenzyl)-4- substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4,5-e][1, 2, 4]thiadiazines. , 2006; 29, No 11, 957-962　　　　　　1. Xinyong Liu*, Niangen Chen, Yinzhang Yan, Wen-fang Xu. Design and Synthesis of N4-Substituted Pyrazolo[4,5-e][1,2,4] Thiadiazine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. . 2005; Vol. 25, Suppl., 701　　2. Xianchao Cheng, Xinyong Liu* Wenfang Xu. Recent advances in the structural modification of ligustrazine; cerebro- and cardiovascular activity of ligustrazine derivatives. , 2005; 30(10): 1059.　　3. Xin Yong Liu*, Wen Fang Xu, Jing De Wu. Synthesis of 4-Amino-5-furyl-2-yl-4H-1, 2, 4-triazole-3-thiol Derivatives as a Novel Class of Endothelin(ET) Receptor Antagonists.  (CCL); 2003, 14(8):790-793 　　4. Zeng Bao-Shan, Chen Min-Bo*, Dong Xi-Cheng, Liu Xin-Yong*. q2 Guided Conformation Selection Approach of CoM FA for HIV-1 RT Inhibitors. , 2003; 61(7): 1121-1128　　5. Xinyong Liu*, Zhang Rui and Wenfang Xu. Synthesis of The Novel Liqustrazine Derivatives and Their Protective Effect on Injured Vascular Endothelial Cell Damaged by Hydrogen Peroxide. ; 2003; 13: 2123-2126平度   